Viking Therapeutics (VKTX) Payables (2016 - 2025)
Historic Payables for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to $4.4 million.
- Viking Therapeutics' Payables rose 163740.16% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year increase of 163740.16%. This contributed to the annual value of $9.8 million for FY2024, which is 3063.1% up from last year.
- Viking Therapeutics' Payables amounted to $4.4 million in Q3 2025, which was up 163740.16% from $5.5 million recorded in Q2 2025.
- Viking Therapeutics' Payables' 5-year high stood at $11.1 million during Q2 2024, with a 5-year trough of $254000.0 in Q3 2024.
- Over the past 5 years, Viking Therapeutics' median Payables value was $5.2 million (recorded in 2024), while the average stood at $5.3 million.
- In the last 5 years, Viking Therapeutics' Payables plummeted by 9555.24% in 2024 and then surged by 163740.16% in 2025.
- Quarter analysis of 5 years shows Viking Therapeutics' Payables stood at $1.4 million in 2021, then surged by 490.65% to $8.5 million in 2022, then fell by 11.92% to $7.5 million in 2023, then skyrocketed by 30.63% to $9.8 million in 2024, then tumbled by 55.03% to $4.4 million in 2025.
- Its Payables stands at $4.4 million for Q3 2025, versus $5.5 million for Q2 2025 and $7.7 million for Q1 2025.